Abstract
The novel coronavirus disease 2019 (COVID-19) pandemic has caused catastrophic damage to human life across the globe along with social and financial hardships. According to the Johns Hopkins University Coronavirus Resource Center, more than 41.3 million people worldwide have been infected, and more than 1,133,000 people have died as of October 22, 2020. At present, there is no available vaccine and a scarcity of efficacious therapies. However, there is tremendous ongoing effort towards identifying effective drugs and developing novel vaccines. Early data from Adaptive COVID-19 Treatment Trials (ACTT) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and compassionate use study have shown promise for remdesivir, leading to emergency authorization by the Food and Drug Administration (FDA) for treatment of hospitalized COVID-19 patients. However, several randomized studies have now shown no benefit or increased adverse events associated with remdesivir treatment. Drug development is a time-intensive process and requires extensive safety and efficacy evaluations. In contrast, drug repurposing is a time-saving and cost-effective drug discovery strategy geared towards using existing drugs instead of de novo drug discovery. Treatments for cancer and COVID-19 often have similar goals of controlling inflammation, inhibiting cell division, and modulating the host microenvironment to control the disease. In this review, we focus on anti-cancer drugs that can potentially be repurposed for COVID-19 and are currently being tested in clinical trials.
Keywords: COVID-19; anti-cancer drugs; drug-repurposing.
【저자키워드】 COVID-19, anti-cancer drugs, drug-repurposing., 【초록키워드】 Treatment, coronavirus disease, Inflammation, Coronavirus disease 2019, Efficacy, Vaccine, coronavirus, pandemic, Infectious diseases, Drug discovery, Vaccines, Drug development, Cancer, Remdesivir, clinical trials, drug, Infectious disease, novel coronavirus disease, FDA, Novel coronavirus, Food and Drug Administration, effective drugs, adverse events, adverse event, allergy, Therapies, compassionate use, food, scarcity, life, focus, Johns Hopkins, cell division, hospitalized COVID-19 patients, promise, effort, center, randomized study, present, novel vaccines, NIAID, de novo, microenvironment, Host, benefit, Cell, Johns Hopkins University, catastrophic, shown, tested, caused, globe, died, the disease, inhibiting, effective drug, modulating, 【제목키워드】 repurposing, drug,